What records are connected here?
- Evidence lanes
- 1
- Source years
- 7
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1,4Evidence: Smaller human trialsHormones
Also called Examorelin1
Hexarelin is a synthetic six-amino-acid peptide that FDA’s substance registry lists under the international name examorelin.1 Small studies in healthy volunteers found that it raises growth hormone and also stress and lactation hormones such as cortisol and prolactin, and that it reduced deep sleep in one study of seven people.2,3 No FDA approval is reported in the sources reviewed here. Hexarelin does not appear on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,4,6
| What it is | A synthetic hexapeptide amide containing 2-methyl-D-tryptophan, recorded as examorelin, hexarelin and EP-23905 in FDA’s substance registry.1 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list hexarelin.1,4 |
| Human evidence | Small, short hormone studies in healthy volunteers, including a placebo-controlled study of seven people and a randomized study of six men.2,3 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Hexarelin is a synthetic peptide of six amino acids, His-(2-methyl)D-Trp-Ala-Trp-D-Phe-Lys-NH2. FDA’s substance registry records it as examorelin, its international name, and as hexarelin, EP-23905 and MF-6003.1
Study authors describe hexarelin as a synthetic growth hormone secretagogue, a compound that acts at the same receptor as the natural hormone ghrelin to prompt the pituitary to release growth hormone.2
In a separate test within the same study, hexarelin also raised ACTH, cortisol and prolactin, showing that its effects are not limited to growth hormone.3
In a 2004 placebo-controlled study of seven healthy young volunteers, hexarelin reduced the deepest stage of sleep and raised growth hormone, prolactin, ACTH and cortisol during the night.2
In a 2002 study of six healthy young men, repeated hexarelin over one day raised 24-hour growth hormone release without changing IGF-I, prolactin, ACTH or cortisol, and it blunted the growth hormone response to a later test.3
These studies lasted a day or two and measured hormones; none of the sources reviewed here tests whether hexarelin treats any condition.2,3
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of hexarelin by FDA.1,4
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list hexarelin, either in category 2 or among withdrawn nominations.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Hexarelin is not among them.5,6
Whether it is effective or safe for any condition, or with longer use: the studies cited here were small and lasted a day or two.2,3
Whether its effect on deep sleep, seen in seven volunteers, would appear in larger groups.2
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Hexarelin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Hexarelin are a bounded selection, not every registration or paper about Hexarelin. For the years before Hexarelin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Hexarelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Hexarelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported. Human data come from small, short hormone studies in healthy volunteers. Hexarelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported. Human data come from small, short hormone studies in healthy volunteers. Hexarelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 19, 2026
Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver.↗Source date October 19, 2026Literature metadata · added November 16, 2026
Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa.↗Source date October 12, 2026Literature metadata · added November 16, 2026
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.↗Source date March 9, 2022PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
24 of 24 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PubMed lists PMID 10469018 in Clinical endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 10512687 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 10611139 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
24 with attributed title, venue, publication-date, and type metadata.
Selected records span November 15, 2012 to October 19, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 9279881 in Pharmaceutical research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 9258804 in Journal of endocrinological investigation as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 11238504 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2001-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 9801989 in Journal of endocrinological investigation as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 18288286 in PPAR research as Journal Article, with publication-date metadata of 2008 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 18787392 in Journal of endocrinological investigation as Letter, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 32403043 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2020-05-08 (day precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 11959048 in European journal of heart failure as Comparative Study, Evaluation Study, Journal Article, with publication-date metadata of 2002-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 22401277 in Reproduction, fertility, and development as Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 10990150 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Clinical Trial, Journal Article, with publication-date metadata of 1998-04 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 11445244 in Peptides as Journal Article, with publication-date metadata of 2001-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 10469018 in Clinical endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
Psychoneuroendocrinology · Official source · Source checked November 15, 2026
European Journal of Endocrinology · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026